Abstract: Slide Presentations |

Which Is More Steroid Sparing in Persistent Bronchial Asthma: Montelukast Or Theophylline? FREE TO VIEW

Ashish R. Shah, MD
Author and Funding Information

B.J. Medical College & Civil Hospital, Ahmedabad, India


Chest. 2003;124(4_MeetingAbstracts):106S-c-107S. doi:10.1378/chest.124.4_MeetingAbstracts.106S-c
Text Size: A A A
Published online


PURPOSE:  The objective of the present study was to determine whether addition of either oral sustained release theophylline or montelukast, an oral leukotriene receptor antagonist, to inhaled corticosteroids, resulted in improvement of clinical symptoms and pulmonary function parameters or not.

METHODS:  90 patients with chronic asthma (FEV1 50 to 85% of predicted) incompletely controlled with inhaled budesonide, 200 μg twice daily, were allocated, in a randomized, double-blind fashion, to one of three treatment groups: double dose of inhaled budesonide, oral sustained release theophylline in addition to budesonide and Montelukast 10 mg plus budesonide. The primary endpoints were FEV1 and PEFR. Pulmonary function tests were carried out at the onset of treatment, at end of 2, 4 and lastly at 8 weeks.

RESULTS:  Patients in all groups showed a decrease in intensity of clinical features. PFT at 8 weeks showed an improvement from 211.8± 10.4 to 226.2 ± 9.1, 205.2 ± 11.4 to 223.8 ± 8.4 and 210.6 ± 11.6 to 243.6 ± 10.0 (P< 0.05) in PEFR and from 2.12 ± 0.12 to 2.31 ± 0.18, 2.07 ± 0.08 to 2.28 ± 0.10 and 2.02 ± 0.08 to 2.32 ± 0.10 (P < 0.05) in FEV1.

CONCLUSION:  Use of oral leukotriene receptor antagonist along with inhaled bronchodilators and corticosteroids has a superior effect than addition of an oral sustained release theophylline or an increase in the dose of inhaled corticosteroids on clinical and pulmonary function parameters in patients of chronic bronchial asthma.

CLINICAL IMPLICATIONS:  Addition of montelukast to low dose inhaled glucocorticoids results in significant improvement in lung function parameters and supports it use as a steroid sparing agent.

DISCLOSURE:  A.R. Shah, None.

Tuesday, October 28, 2003

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Management of asthma.
Singapore Ministry of Health | 7/18/2008
Treatment of acute exacerbation of asthma.
Finnish Medical Society Duodecim | 1/25/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543